Deciphera Pharmaceuticals (DCPH) Given Daily Coverage Optimism Rating of 0.00
Media headlines about Deciphera Pharmaceuticals (NASDAQ:DCPH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave news headlines about the company an impact score of 48.0259003694413 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Deciphera Pharmaceuticals stock opened at $24.13 on Tuesday. The firm has a market capitalization of $833.43 and a price-to-earnings ratio of -8.07. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $29.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.35 and a quick ratio of 14.35.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Wednesday, March 28th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.19). equities research analysts forecast that Deciphera Pharmaceuticals will post -2.36 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Deciphera Pharmaceuticals (DCPH) Given Daily Coverage Optimism Rating of 0.00” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2018/04/17/deciphera-pharmaceuticals-dcph-given-daily-coverage-optimism-rating-of-0-00.html.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.